Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque
Francesca L. Celletti, MDa,
Paul R. Hilfiker, MDa,
Paras Ghafouri, BSa and
Michael D. Dake, MDa
a Department of Cardiovascular and Interventional Radiology, Stanford University Medical Center, Stanford, California, USA

View larger version (50K):
[in a new window]
|
Figure 1 Representative photomicrographs at seven days. Low-magnification (x8, before 50% reduction) photographs of thoracic aortic cross sections stained with Verhoeff and counterstained with hematoxylin from (A) a rabbit treated with rhVEGF (2 µg/kg by a single intramuscular injection) and (B) an albumin-treated rabbit.
|
|

View larger version (59K):
[in a new window]
|
Figure 2 Representative photomicrographs at 21 days. Low-magnification (x8, before 50% reduction) photographs of thoracic aortic cross sections stained with Verhoeff and counterstained with hematoxylin from (A) a rabbit treated with rhVEGF (2 µg/kg by a single intramuscular injection) and (B) an albumin-treated rabbit.
|
|
|